96 results about "Companion diagnostic" patented technology

The invention relates to the technical field of biological medicine, in particular to a T cell receptor targeting AFP peptide, a preparation method of the T cell receptor and a companion diagnostic kit. A T cell receptor targeting an AFP peptide is provided, the sequence of the AFP peptide is FMNKFIYEI, and the T cell receptor comprises a TCR [alpha] chain variable domain and a TCR [beta] chain variable domain. Corresponding nucleic acid molecules, vectors and host cells, and methods of making T cell receptors are provided. Further provided is a companion diagnostic kit containing the cell receptor. The invention provides a better choice for concomitant diagnosis and treatment products of cells of alpha fetoprotein (AFP).

The invention discloses a detection kit and method for detecting allergic inflammatory factors based on a centrifugal micro-fluidic chip, and relates to the field of kits, the detection kit comprises the centrifugal micro-fluidic chip and a preset reagent; the centrifugal micro-fluidic chip comprises a chip base body, a sample adding cavity, a liquid level sensor, a liquid level sensor, a liquid level sensor, a liquid level sensor and a liquid level sensor, the nucleic acid extraction and purification cavity comprises a plurality of amplification cavities; a reagent storage chamber; a waste liquid chamber; and a capillary valve. The functions of nucleic acid extraction, variable temperature amplification and multi-target synchronous detection are integrated through the centrifugal micro-fluidic chip, full-closed operation is achieved by means of centrifugal force or other driving force such as air pressure and electroosmotic flow, and the pollution risk caused by manual step-by-step operation is thoroughly eliminated; a multi-wavelength distinguishable fluorescent probe and a grouping preset primer combination are adopted to synchronously complete parallel detection of the allergic inflammatory factor mRNA and the drug accompanying diagnosis target, cross interference is avoided, and large instruments and equipment do not need to be relied on.

Automated systems and methods are presented for retrospectively analyzing clinical trial data. A plurality of image derived from biological samples of patients in a cohort population are accessed. Image features are computed based on the plurality of images. A diagnostic feature metric is derived based on the computed image features. A cut point value is determined by applying a statistical minimization method using the derived diagnostic feature metric and patient outcome data from the cohort population, in which the cut point value identifies a patient in the cohort population as positive or negative for a diagnostic test.

The invention relates to the technical field of biological medicine, in particular to a T cell receptor targeting AFP peptide, a preparation method of the T cell receptor and a companion diagnostic kit. A T cell receptor targeting an AFP peptide is provided, the sequence of the AFP peptide is FMNKFIYEI, and the T cell receptor comprises a TCR [alpha] chain variable domain and a TCR [beta] chain variable domain. Corresponding nucleic acid molecules, vectors and host cells, and methods of making T cell receptors are provided. Further provided is a companion diagnostic kit containing the cell receptor. The invention provides a better choice for concomitant diagnosis and treatment products of cells of alpha fetoprotein (AFP).

The present invention provides methods of identifying mitochondrial function regulators for use in the treatment of neurodegenerative disorders. The invention provides methods for identifying subjects that can benefit from the therapeutic agent. Aspects of the methods include administering a MIRO1 reducing agent to a subject suffering from Parkinson's disease. The invention also provides companion diagnostic assays to determine whether a subject is suitable for receiving MIRO1 reducing agent treatment and treat the subject according to the results.

Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

The present invention relates to a depression disease management system based on targeted metabolomics and machine learning models. The system comprises an intelligent diagnostic model module, a differential diagnostic model module, a hierarchical diagnostic model module, a companion diagnostic model module, a treatment endpoint outcome prediction model module, a relapse prediction model module, and a comprehensive judgment module. The system provided by the present invention can address current clinical challenges in depression diagnosis, treatment outcomes, and relapse, enabling accurate diagnosis, timely treatment, and improving the mental health of the general population.

The invention provides biomarkers to predict effective treatment of cancer using an IAP antagonist. Identifying one or more of the identified biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an IAP antagonist. Accordingly, the invention relates generally to a companion diagnostic for IAP antagonist therapy. In particular, the biomarkers include IL-2Rα, IL-6r, CRP, EPO, CD27, CD40, TN-C, IL-18, PLGF, TNFrl and MCP-4.

Providing a CDKN2a companion diagnostic for interferon therapy for bladder cancer. [Solution] A method for treating bladder cancer, comprising the steps of: diagnosing bladder cancer in a human; measuring the CDKN2A expression level in the human; and subsequently injecting an interferon expression-inducing agent into the human. Non-muscle-invasive bladder cancer (NMIBC) represents the most common disease state in patients with newly diagnosed bladder cancer. Those with high-grade (HG) tumors are at significant risk of both recurrence and progression.

The purpose of the present invention is to provide a technique for imaging the brain of a live animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brainparmeability, high receptor selectivity and high quantitativity, is used for imaging a live animal body. A dibenzoazepine derivative is used for treating a disease in which hM4D receptor or hM3D receptor participates. Further, a radiolabeled dibenzoazepine derivative is used for imaging an axonal end which is innervated by a nerve cell.

[Problem] Provided are a new marker of disease activity useful for testing a diseased state of vasculitis or an exacerbation risk of COVID-19, and a means for testing a diseased state of vasculitis or an exacerbation risk of COVID-19 using the marker. [Solution] According to an aspect of the present invention, there are provided a method for testing a diseased state of vasculitis and a method for testing an exacerbation risk of COVID-19, the method including: detecting or quantifying, in a blood sample collected from a subject, (1) a No. 1 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 23 to 25 kDa, and / or (2) a No. 2 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 16 to 20 kDa.

The present invention relates to the field of biomedical technologies, and particularly to a T cell receptor targeting an AFP peptide, a preparation method thereof, and an accompanying diagnostic kit. A T cell receptor targeting an AFP peptide is provided, the sequence of the AFP peptide is FMNKFIYEI, and the T cell receptor comprises a variable domain of the TCRα chain and a variable domain of the TCRβ chain. Corresponding nucleic acid molecules, vectors, and host cells are provided, as well as a method for preparing the T cell receptor. An accompanying diagnostic kit containing the cell receptor is further provided. The present invention provides a better choice for products for the accompanying diagnosis and treatment of cells of alpha-fetoprotein (AFP).

Disclosed is a method for determining the expression of PD-L1 that is based on a RT-qPCR in a RNA sample of, for example, Circulating Tumor Cells (CTC) or fresh frozen primary tumor tissues. In particular, a method is disclosed for the detection of PD-L1 mRNA positive CTCs or primary tumor tissues (fresh frozen) based on the quantitative determination of the molecular marker (PD-L1) in biological samples of patients suffering from cancer. In use, detection can take place before, during or after immune therapy or any other treatment in order to provide significant information concerning the guiding or the monitoring of the anti-PD-L1 agents effectiveness. This RT-qPCR assay could comprise a promising companion diagnostic test in order to evaluate the PD-L1 expressional status on CTC or tumor tissue, providing clinical applications, which could have an important impact on therapeutic interventions since the expression of PD-L1 is associated with response to immunotherapy.

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet. In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet, especially to determine the likelihood that the dietary intervention may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.

The present disclosure in one aspect provides technologies for detection of esophageal cancer, e.g., early detection of esophageal cancer. In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to esophageal cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

The application provides application of serum sIL-2R as an ADAM10 inhibitor companion diagnostic marker and a corresponding kit, including two core application scenarios: before treatment, screening of a patient population with high activity of an ADAM10-sIL-2R pathway and most likely to benefit from ADAM10 inhibitor treatment by detecting the serum sIL-2R level of the patient; during and after treatment, evaluating the inhibition effect of the ADAM10 inhibitor on the target pathway and the treatment efficacy by dynamically monitoring the change of the serum sIL-2R level; the liquid companion diagnostic strategy will provide an indispensable supporting tool for the precise application of the ADAM10 inhibitor in pancreatic cancer, and significantly improve the precision and effectiveness of clinical medication.

The disclosure provides binding agents (e.g., antibodies) against a human Hepatitis A virus cellular receptor 2 protein (TIM3), as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting Non-Small Cell Lung Cancer (NSCLC) and / or other types of lung cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) or other types of liver cancer, Renal cell carcinoma, malignant melanoma, gastro-intestinal cancer, colorectal cancer, urothelial carcinoma and other types of bladder cancer, mamma carcinoma and / or other types of breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, lymphoma / leukemia, malignant mesothelioma, or a cancer in another organ or cell type.

Provided are: a novel pathological marker which is useful in the examination of the progression of vasculitis and the examination of the risk of severity of COVID-19; and a means for examining the progression of vasculitis and the risk of severity of COVID-19 using the marker. According to one embodiment of the present invention, provided are: a method for checking the afflicted state of vasculitis; and a method for checking the critical risk of COVID-19. The method comprises: detecting or quantifying the following proteins in a blood sample collected from a subject: (1) a first APOA2-like protein having a molecular weight of 23-25 kDa and / or a second APOA2-like protein having a molecular weight of 23-25 kDa and / or a third APOA2-like protein having an antigen-antibody reaction with a single-chain variable fragment containing an amino acid sequence represented by SEQ ID NO: 1; (2) A second APOA2-like protein having a molecular weight of 16-20 kDa, said second APOA2-like protein having an antigen-antibody reaction with a single-chain variable fragment comprising the amino acid sequence represented by SEQ ID NO: 1.

The application discloses a molecular probe and a preparation method and application thereof, and relates to the technical field of fluorescent probes.The structural formula of the molecular probe is as follows: the application takes two identical corrole units covalently connected as a parent body, and simultaneously introduces a reduced glutathione response group into the two corrole units, so that a molecular probe, namely a double-corrole molecular probe, which can remove reduced glutathione and realize NIR-II fluorescent signal opening, is constructed.The molecular probe can induce cell ferroptosis by consuming reduced glutathione in tumor cells.In addition, the molecular probe itself has a high photothermal conversion efficiency, and can perform photothermal treatment on tumor cells.Therefore, the molecular probe provided by the application is a companion diagnostic reagent integrating NIR-II fluorescent response, ferroptosis induction and photothermal treatment, has excellent antitumor effect, and has a wide application prospect.

The present invention relates to phage therapy. More specifically, the present invention relates to novel phages with high specificity for Staphylococcus aureus strains, their manufacture, their components, compositions comprising them, and their use in phage therapy and as companion diagnostics.

The invention discloses a marker for evaluating the curative effect and survival prediction of a tumor-targeted CLDN18.2 therapeutic drug and application of the marker. The invention provides a binding strength of extracellular vesicles and MNA-G, IAA, VVL and LAL lectin molecules and a derivative combination score or model thereof as a curative effect marker of a digestive tract tumor targeted CLDN18.2 therapeutic drug (such as a tumor targeted CLDN18.2 CAR-T therapeutic scheme) and application of the therapeutic marker, and the therapeutic marker can be used for dividing effective crowds, predicting the therapeutic effect, monitoring the occurrence of drug resistance and improving the therapeutic effect of the digestive tract tumor targeted CLDN18.2 therapeutic drug. The CLDN18.2-targeted CLDN18.2 marker has a specific marker potential for cell treatment drugs and antibody drugs, is expected to promote development of companion diagnosis means of a targeted CLDN18.2 treatment scheme, and accumulates precious experience for clinical practice of the CLDN18.2 targeted treatment drugs in the future.

Provided herein are methods and compositions for determining if a subject diagnosed with a CEACAM1-related disease or disorder is administered a CEACAM1 antibody or antigen-binding agent as a treatment.

The invention relates to the technical field of clinical molecular diagnosis and individualized tumor medicine, in particular to a group of children leukemia prognosis biomarkers based on mitochondrial activity and application of the children leukemia prognosis biomarkers. The invention aims to provide a group of children leukemia prognosis biomarkers based on mitochondrial activity, the children leukemia prognosis biomarkers are used for quantifying mitochondrial metabolic activity of children B-ALL patients, and the biomarkers can be used for early prediction of recurrence risk, evaluation of early curative effect and long-term outcome and guidance of application of a BCL-2 inhibitor or an OXPHOS inhibitor. The marker can be used as an accompanying diagnostic marker for predicting the chemotherapy recurrence risk and the reaction of a targeted drug (such as venetoclax); meanwhile, the children leukemia prognosis biomarker provided by the invention can be used as an accompanying diagnostic tool for ALL risk stratification and metabolism targeted therapy (such as a BCL-2 inhibitor) reaction prediction, and the consistency is verified in multiple queues in the specific embodiment of the invention, so that the children leukemia prognosis biomarker is high in clinical generalization performance.

1. Name of the product of this design: Packaging box (protein in vitro companion diagnostic reagent 2). 2. Purpose of this design product: This design product is used for packaging products. 3. The key design point of this design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the design points: Stereoscopic drawing 1. 5. Other situations that require explanation Other explanations: The gray square coated area in the right view and stereoscopic view 1 is the QR code display area.

A use of Niemann-Pick C1 (NPC1) protein and a substance that inhibits NPC1 gene expression and / or protein activity, which is selected from at least one of the following (a)-(h): (a) for the preparation of kits for diagnosing cancer; (b) for the preparation of kits for predicting the prognosis of cancer; (c) for the preparation of kits for performing a companion diagnostic for cancer treatment; (d) for the preparation of drugs for the prevention and / or treatment of cancer; (e) for the preparation of drugs for the prevention and / or treatment of cancer spread and metastasis; (f) for the preparation of drugs for promoting apoptosis of cancer cells; (g) for the preparation of drugs for inhibiting cancer cells from developing into cancer; (h) for the preparation of drugs for inhibiting in vitro proliferation and growth of cancer cells.

The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

A method for multiplex analysis of amplification products using fluorescence-based multiple melting analysis is capable of analyzing multiple target nucleic acid sequences simultaneously in real time. A kit for performing the multiplex analysis contains target-specific primer / probe sets. The method and the kit allow a detection of multiple target nucleic acid sequences by a single polymerase chain reaction using a single fluorescence channel, thereby significantly reducing time and cost for multiplex nucleic acid detection. Therefore, the method and kit may be widely used in the companion diagnostic field in which multiple target nucleic acid genes need to be analyzed, the agricultural and livestock field in which multiple alleles need to be analyzed, and the clinical pathology field in which multiple infectious agents need to be analyzed simultaneously.

A companion diagnostic method, kit, and integrated system for quantifying expression of Prostaglandin Reductase 1 (PTGR1) in a patient sample are disclosed. When the measured expression equals or exceeds a predetermined threshold, the patient is selected to receive hydroxyurea methylacylfulvene (LP-184) or a related acylfulvene. The invention enables personalized cancer therapy, improves objective response rates, and minimizes unnecessary exposure to ineffective treatment. Also provided are pharmaceutical combinations, uses, and claims for treating PTGR1 -positive solid tumors and hematological malignancies.

The present invention relates to methods for the treatment and diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), said methods comprising detecting the presence or absence of a somatic mutation in the DNA of one or more gene specified herein, wherein the presence of a somatic mutation in said one or more gene indicates that the subject has or is at risk of having MASH. Also provided is a method of detecting the presence or absence of a somatic mutation in a subject suspected of having or at risk of having metabolic dysfunction-associated steatohepatitis (MASH) comprising said steps. Methods of treatment herein further comprise administering to the subject an siRNA that inhibits expression of said one or more gene and / or administering a therapeutic intervention described herein if a somatic mutation is present in the DNA. dsRNA molecules comprising a sense strand and an antisense which comprise nucleotides of or nucleotides complementary to any mRNA sequence represented by sequences described herein.